Bioshares latest addition included an update on Opthea.
Here are a few edited highlights. Opthea is building a compelling case for its ophthalmology drug candidate,OPT-302. Having delivered positive results in the first indication of wet AMD in a PhaseIb/IIa trial last year, it has now produced early positive data from its Phase Ib/IIa study indiabetic macular edema. It is also strengthening the scientific rationale that underpinsits technology, which will support a future commercial transaction of OPT-302.
In relation to the DME trial. In the five patients with bilateral disease, Opthea plus Eylea achieved a mean 10 lettergain in vision compared to only a 2.6 letter improvement in patients receivingEylea in the second eye. The combinationtreatment achieved a central subfield thickness reduction of 80uM compared to just a 6uM reduction in theEylea only treatment alone.
It was also explained why the mechanism of action of OPT-302 may have efficacy in DME
The company expects to receive a $12 million tax rebate forlast financial year.
Although data for its two trials is between 12 - 18 months away,investors with patience may be very well rewarded with this stock.The company's core asset OPT-302 has the potential to deliversubstantial value to the company if positive trial data continues to flow.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Reports Positive Data from Ph1b DME Study of OPT-302
Ann: Opthea Reports Positive Data from Ph1b DME Study of OPT-302, page-5
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
83.5¢ |
Change
-0.005(0.60%) |
Mkt cap ! $1.027B |
Open | High | Low | Value | Volume |
85.5¢ | 85.5¢ | 82.0¢ | $11.20M | 13.42M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13018 | 83.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
84.0¢ | 3897 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13018 | 0.830 |
2 | 14230 | 0.825 |
3 | 17895 | 0.820 |
4 | 31905 | 0.815 |
3 | 14224 | 0.810 |
Price($) | Vol. | No. |
---|---|---|
0.840 | 3897 | 1 |
0.850 | 9739 | 1 |
0.855 | 20950 | 3 |
0.860 | 13018 | 1 |
0.865 | 83653 | 6 |
Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |